

## Corrigendum

# The uracil–DNA glycosylase UNG protects the fitness of normal and cancer B cells expressing AID

Shiva Safavi<sup>1,2</sup>, Ariane Larouche<sup>1,†</sup>, Astrid Zahn<sup>1,†</sup>, Anne-Marie Patenaude<sup>1</sup>, Diana Domanska<sup>3,4</sup>, Kiersten Dionne<sup>1</sup>, Torbjørn Rognes<sup>3,5</sup>, Felix Dingler<sup>6</sup>, Seong-Kwi Kang<sup>7</sup>, Yan Liu<sup>4</sup>, Nathalie Johnson<sup>2,8</sup>, Josée Hébert<sup>9,10</sup>, Ramiro E. Verdun<sup>11,12</sup>, Cristina A. Rada<sup>6</sup>, Francisco Vega<sup>11,13</sup>, Hilde Nilsen<sup>4,14</sup> and Javier M.D. Noia<sup>1,2,9,\*</sup>

<sup>1</sup>Institut de Recherches Cliniques de Montréal, 110 Av des Pins Ouest, Montréal, QC H2W 1R7, Canada, <sup>2</sup>Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, QC H4A 3J1, Canada, <sup>3</sup>Department of Informatics, University of Oslo, PO Box 1080, Blindern, 0316 Oslo, Norway, <sup>4</sup>Section for Clinical Molecular Biology, Akershus University Hospital, PO 1000, 1478 Lørenskog, Norway, <sup>5</sup>Department of Microbiology, Oslo University Hospital, Rikshospitalet, Oslo NO-0027, Norway, <sup>6</sup>MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK, <sup>7</sup>ITR Laboratories Canada, Inc., 19601 Clark Graham Ave, Baie-D'Urfe, QC H9 × 3T1, Canada, <sup>8</sup>Jewish General Hospital, Montreal, QC H3T 1E2, Canada, <sup>9</sup>Department of Medicine, Université de Montréal, C.P. 6128, Montreal, QC H3C 3J7, Canada, <sup>10</sup>The Quebec Leukemia Cell Bank, Research Centre and Division of Hematology—Oncology, Maisonneuve-Rosemont Hospital, 5415 l'Assomption Blvd, Montreal, QC H1T 2M4, Canada, <sup>11</sup>Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA, <sup>12</sup>Geriatric Research Education and Clinical Center, Miami VA Healthcare System, Miami, FL 33136, USA, <sup>13</sup>Division of Hematopathology, Department of Pathology and Laboratory Medicine, University of Miami and Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA and <sup>14</sup>Institute of Clinical Medicine, University of Oslo, P.O. box 1171, Oslo, Norway

NAR Cancer, Volume 2, Issue 3, September 2020, zcaa019, <https://doi.org/10.1093/narcan/zcaa019>

The Authors wish to add another source of Funding (in bold):

### FUNDING

Canadian Cancer Society Research Institute [700348 to J.M.D.N.]; Leukemia and Lymphoma Society of Canada [514661 to J.M.D.N.]; Norwegian Cancer Society [182793–2016 to H.N.]; Southern and Eastern Norway Regional Health Authority [276940 to Y.L.]; Fonds de Recherche du Québec—Santé ‘Bourse de Merite’ (to J.M.D.N.); NIH/NIGMS [R01GM121595 to R.E.V.]; NHI/NCI [P30CA240139 to R.E.V.].

The published article has been updated.

\*To whom correspondence should be addressed. Tel: +1 514 987 5642; Email: [javier.di.noia@ircm.qc.ca](mailto:javier.di.noia@ircm.qc.ca)

†The authors wish it to be known that, in their opinion, the second and third authors should be regarded as Joint Second Authors.